Dec 24, 2025 • Sahm
NEUTRAL
Oscar Health (OSCR): Reassessing Valuation as Regulatory and Competitive Pressures Intensify in Georgia
Oscar Health (OSCR) is facing renewed scrutiny due to intensifying regulatory and competitive pressures, particularly in the Georgia market, which could impact its profitability. Despite a recent recovery in share price and strong longer-term shareholder returns, the stock's current valuation, slightly above Wall Street targets, raises questions about whether it is overvalued amidst these risks. Analysts have a consensus price target of $11.143, with a fair value narrative suggesting slight overvaluation, while market multiples indicate potential value.
Dec 15, 2025 • Sahm
NEUTRAL
Oscar Health (OSCR): Reassessing Valuation After New Analyst Coverage and Broward Health Network Expansion
Oscar Health (OSCR) has gained attention due to new analyst coverage from Stephens and Co. and a partnership with Broward Health. While a narrative fair value suggests the stock is 15.7% overvalued at $14.38, its price-to-sales ratio indicates it might be undervalued compared to peers, implying market sentiment is overly cautious. The article suggests investors consider both the promising growth forecasts and the current market multiples when evaluating OSCR.
Dec 08, 2025 • Sahm
NEUTRAL
Can Oscar Health (OSCR) Turn Claims Volatility Into an Edge With Its Tech-Driven Platform?
Oscar Health, despite facing higher-than-expected claims losses earlier in the year, saw a 23% revenue increase in Q3 2025 and has growing membership exceeding 2 million, supported by its tech-driven platform. The company's 2025 guidance projects significant revenue growth and a reduced loss from operations, although analyst views on its fair value vary widely. Investors are closely monitoring medical loss ratio normalization and execution on pricing to gauge the company's long-term profitability.
Dec 06, 2025 • Sahm
NEUTRAL
Oscar Health (OSCR): Revisiting Valuation After Analyst Upgrade and Bullish Options Signal Growing Investor Confidence
Oscar Health (OSCR) has seen a surge in investor confidence following bullish options activity and an analyst upgrade, despite still reporting losses. The company's stock has shown strong year-to-date and three-year returns, sparking debate on whether its current valuation is justified. While some metrics suggest Oscar Health is overvalued, others like its low price-to-sales ratio indicate potential undervaluation.
Dec 01, 2025 • Sahm
NEUTRAL
Oscar Health (OSCR): Evaluating Valuation After Policy Proposal Sparks Investor Optimism
Oscar Health (OSCR) shares surged after news of a potential two-year extension of Obamacare subsidies and expanded eligibility, sparking investor optimism despite the company's valuation being deemed "Overvalued" by analysts at $12.88. While the stock's one-year return is modest, its three-year return shows significant growth. The article also notes Oscar Health's low price-to-sales ratio compared to industry peers, suggesting potential for upside if market sentiment shifts.
Dec 01, 2025 • Sahm
BULLISH
Why Oscar Health (OSCR) Is Up 33.3% After Analysts Highlight Resilience Amid ACA Subsidy Uncertainty
Oscar Health (OSCR) saw a significant stock boost after analysts at Piper Sandler upgraded its rating, citing the company's resilience in gaining market share and improving profitability despite potential ACA subsidy uncertainties. The prospect of extended Affordable Care Act subsidies is highlighted as a key factor that could provide stability and consistent membership for Oscar Health, influencing its investment narrative positively. While Oscar Health shows growth in revenue and membership, profitability remains a challenge due to high operating costs.